Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.66 |
| ▸ | CNR1 | P21554 | 8/20 | 0.65 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.65 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.65 |
| ▸ | FAAH | O00519 | 2/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.65 |
| ▸ | GPR183 | P32249 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.65 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25258533 | 1.00 | CNR2 (0.66) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL25268322 | 0.91 | CNR2 (0.61) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL22946285 | 0.91 | CNR2 (0.61) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL23765260 | 0.91 | CNR2 (0.61) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL23765328 | 0.89 | CNR2 (0.59) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL12715211 | 0.88 | CNR2 (0.72) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL14288906 | 0.87 | CNR2 (0.65) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL14288905 | 0.87 | CNR2 (0.65) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL29949504 | 0.87 | CNR2 (0.71) | CNR2CNR1ABHD12ABHD6FAAH | |
| SCHEMBL5095777 | 0.87 | CNR2 (0.77) | CNR2CNR1ABHD12ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059152-A1 | CATALYTIC TETRAHYDROCANNABINOL SYNTHESIS AND PRECURSORS | KARE CHEMICAL TECH INC (CA) | 2025-02-20 | — | — | US | disclosed |
| WO-2023102655-A1 | CATALYTIC TETRAHYDROCANNABINOL SYNTHESIS AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023102655-A1 | CATALYTIC TETRAHYDROCANNABINOL SYNTHESIS AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059152-A1 | CATALYTIC TETRAHYDROCANNABINOL SYNTHESIS AND PRECURSORS | CNR2, CNR1, CES2 | CNR2 1/4885CNR1 2/4885ABHD12 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.